After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...

A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...

Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — ...

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The ...

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

NEW YORK (PIX11) — A young man, homeless and disheveled, was surrounded by a joint response team made up of two NYPD officers ...

Dec. 11, 2024 — Investigators who previously found that a daily statin pill helps prevent heart attacks and strokes in people with HIV have now discovered a potential mechanism that may help to ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. | The Fierce Biotech Fundraising Tracker records ...

Watch BBC's Steve Rosenberg challenge Putin on his 25 years in power in Russia. Video, 00:03:33Watch BBC's Steve Rosenberg challenge Putin on his 25 years in power in Russia ...